Amicus Therapeutics Inc.
Amicus Therapeutics Announces 2024 Revenue and 2025 Outlook
Summary
On January 12, 2025, Amicus Therapeutics, Inc. reported its preliminary 2024 revenue of $528 million, showing a 32% year-over-year growth, and provided its strategic outlook for 2025. The company anticipates revenue growth of 17-24% in 2025, driven by strong demand for its therapies Galafold and Pombiliti + Opfolda. Amicus also announced it settled a patent litigation with Teva, securing exclusivity until January 2037. The company expects to achieve positive GAAP Net Income during H2 2025.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement